Results 201 to 210 of about 510,697 (405)

Sex Differences in Response and Persistence to Biologic Therapy in Psoriatic Arthritis: A 52‐Week Analysis With Extended Long‐Term Outcomes

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Psoriatic arthritis (PsA) is a chronic immune‐mediated disease with heterogeneous joint and skin manifestations. Although biologic therapies targeting TNFα, IL‐17, and IL‐23 have transformed PsA management, sex‐specific differences in efficacy and treatment persistence remain underexplored.
Keita Ohyachi   +5 more
wiley   +1 more source

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]

open access: yes, 2009
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A.   +4 more
core   +2 more sources

B-mode ultrasound in the uveitis in the psoriatic arthritis without skin lesion [PDF]

open access: green, 2020
José Alex   +3 more
openalex   +1 more source

POS0227 SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS [PDF]

open access: bronze, 2023
Signe Holm Nielsen   +8 more
openalex   +1 more source

Real‐World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP)

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Generalized pustular psoriasis (GPP) is a heterogeneous, systemic neutrophilic inflammatory disease, characterized by chronic symptoms and recurrent flares, which can be potentially life‐threatening. Spesolimab, an interleukin‐36 receptor antagonist, has been approved to treat GPP flares in many countries including Japan.
Akimichi Morita   +12 more
wiley   +1 more source

44007 Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials [PDF]

open access: bronze, 2023
Kenneth B. Gordon   +7 more
openalex   +1 more source

CXCL4 is a novel inducer of human Th17 cells and correlates with IL‐17 and IL‐22 in psoriatic arthritis [PDF]

open access: hybrid, 2017
Alsya J. Affandi   +7 more
openalex   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy